Bifogade filer
Lifecare’s implant continues to track glucose where traditional CGMs reach their limits
Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Bergen, Norway, 13 January 2026 - Lifecare ASA (LIFE) today reports new findings from its ongoing longevity study LFC-SEN-002, showing that the company’s implantable glucose sensor continues to track glucose changes at high levels where traditional enzyme-based CGM systems experience reduced resolution.
Last week, Lifecare confirmed that its reproducibly manufactured, fully integrated implant tracks glucose in vivo. This new analysis explains why that matters.
A built-in system advantage
Lifecare’s implant measures glucose using a non-enzymatic sensing principle based on osmotic pressure - a natural biological and physical process that scales with concentration. Because the system does not rely on enzyme chemistry, it is not exposed to the same saturation effects that can limit enzyme-based CGMs at high glucose levels.
In practical terms, this means Lifecare’s implant continues to show clear and structured glucose-related signals, even when glucose levels are very high.
Analysis of in-vivo data shows that the implant signal:
- remains directional and structured,
- continues to differentiate glucose changes,
- and behaves consistently with physiological expectations.
What this means
These findings support qualitative interpretation of glucose behaviour, such as distinguishing very high from less high glucose states. Lifecare does not make claims at this stage regarding numerical accuracy, clinical performance, or diagnostic use. Remaining system-level work is focused on optimisation and refinement.
“Because our system does not depend on enzyme reactions, it behaves differently by design,” says Joacim Holter, CEO of Lifecare. “What we are seeing is exactly what we would expect from a non-enzymatic sensing principle: the signal continues to behave coherently even at high glucose levels.”
A clear step forward
This analysis builds directly on the system-level confirmation announced on 8 January 2026 and strengthens Lifecare’s confidence in the robustness and scalability of its implantable CGM platform.
Data from LFC-SEN-002 continue to support:
- further optimisation of long-term stability,
- preparation for veterinary market entry, and
- progress toward first-in-human studies and CE marking.
About LFC-SEN-002
LFC-SEN-002 is an ongoing longevity and performance study evaluating Lifecare’s implantable CGM technology in dogs. The study focuses on biocompatibility, system stability and in-vivo signal behaviour, and supports both veterinary product development and future human clinical programs. The study is conducted under veterinary supervision in cooperation with the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences. Data generated in the study provide direct input to Lifecare’s ongoing development and execution program.